Thus, it is plausible that the suggestive protective effects we observed for PFUnDA and PFHxS that appear to be confined to cases with ER-/PR- tumors could be a spurious artifact of the recommended treatment regimens more commonly prescribed for these breast cancer patients. This evidence concerns the gene ESR1 and breast cancer.